Trial testing copycat cancer drug withdrawn before starting
Disease control
Terminated
This study aimed to compare a new version of the cancer drug pertuzumab (called EG1206A) with the original version (Perjeta) for treating early-stage HER2-positive breast cancer. Patients would have received the drug along with standard chemotherapy and another targeted therapy b…
Phase: PHASE3 • Sponsor: EirGenix, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC